Investor Centre
Our broad clinical and preclinical pipeline in oncology and behavioural brain disorders focuses on indications including glioblastoma, neurodevelopmental disorders, addiction, anxiety, fatigue and narcolepsy.
TheraCryf plc Full Year Results
Voting on AGM Resolutions
18 - July - 2024Results of voting on resolutions following TheraCryf's AGM held on Thursday 18th July 2024.
TheraCryf plc - Research and Development Update
14 - June - 2024TheraCryf plc present an update on the Company including current status of R&D projects.
Company | Analyst |
---|---|
Cavendish | Chris Donnellan |
Capital Access Group | Colin Smith |
Major Shareholder
Current Shareholder | Number of shares | Percentage holding |
---|---|---|
J. R. Kight | 34,600,000 | 8.10% |
Rathbones Investment Management Ltd | 25,789,246 | 6.03% |
First Equity Limited | 25,700,000 | 6.01% |
Octopus Investments | 21,875,000 | 5.12% |
Vulpes Investment Management Pte Ltd | 20,554,191 | 4.81% |
Seneca Partners Limited | 16,301,456 | 3.81% |
The number of ordinary shares in issue is 427,346,895 all of which are in public hands. The Company does not hold any shares in Treasury.